# Chemed Corp: Form 10-Q for the period ended Mar 31, 2014

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2014-05-02
- Accepted by EDGAR: May 2, 2014, 08:50 ET
- Period: 2014-03-31
- Accession: 0001157523-14-001833
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000115752314001833/a50852729.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000115752314001833/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-01-01 to 2014-03-31 | $358.3m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2014-01-01 to 2014-03-31 | $257.8m | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months, 2014-01-01 to 2014-03-31 | $55.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2014-01-01 to 2014-03-31 | $36.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-01-01 to 2014-03-31 | $3.8m | us-gaap:InterestExpense |
| Income tax | 3 months, 2014-01-01 to 2014-03-31 | $13.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-01-01 to 2014-03-31 | $20.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-01-01 to 2014-03-31 | $1.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-01-01 to 2014-03-31 | $1.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2014-01-01 to 2014-03-31 | 18,305,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2014-01-01 to 2014-03-31 | −$11.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 3 months, 2014-01-01 to 2014-03-31 | $8.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2014-01-01 to 2014-03-31 | $3.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2014-01-01 to 2014-03-31 | $33.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2014-03-31 | $39.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-03-31 | $198.4m | us-gaap:AssetsCurrent |
| Total assets | at 2014-03-31 | $868.6m | us-gaap:Assets |
| Current liabilities | at 2014-03-31 | $337.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-03-31 | $422.7m | us-gaap:Liabilities |
| Long-term debt | at 2014-03-31 | $185.8m | us-gaap:LongTermDebt |
| Current portion of debt | at 2014-03-31 | $185.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2014-03-31 | $445.9m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2014-03-31 | 17,539,101 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 38,880 characters.

### Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing and drain cleaning services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

|  | Three months ended March 31, 2014 | 2013 |
| --- | ---: | ---: |
| Service revenues and sales | **$358,300** | $366,641 |
| Net income | **$20,574** | $22,278 |
| Diluted EPS | **$1.12** | $1.17 |
| Adjusted net income | **$23,713** | $26,140 |
| Adjusted diluted EPS | **$1.32** | $1.38 |
| Adjusted EBITDA | **$47,672** | $51,296 |
| Adjusted EBITDA as a % of revenue | **13.3%** | 14.0% |

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”) and Adjusted EBITDA are not measures derived in accordance with GAAP. We use Adjusted Diluted EPS as a measure of earnings for our long-term incentive plan awards. We provide non-GAAP measures to help readers evaluate our operating results, compare our operating performance with that of similar companies that have different capital structures and help evaluate our ability to meet future debt service, capital expenditure and working capital requirements. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures are presented on pages 25-26.

For the three months ended March 31, 2014, the decrease in consolidated service revenues and sales was driven by a 2.7% increase at Roto-Rooter and a 4.0% decrease at VITAS. The increase in service revenues at Roto-Rooter was driven by a 4.8% increase in price and mix shift offset by a 2.4% decrease in job count. The remaining difference relates to increases in contractor revenue. The decrease in service revenues at VITAS was a result of Medicare reimbursement rates increasing 1.4%, offset by a 2.0% decrease as a result of sequestration, decreased ADC of 0.8%, and geographical and level of care mix shift. Consolidated net income decreased 7.6% as a result of the lower revenue at VITAS and higher health insurance costs at Vitas as well as increased advertising expense at Roto-Rooter. Diluted EPS decreased 4.3% as a result of the decrease in net income offset by a lower number of shares outstanding. Adjusted EBITDA as a percent of revenue decreased 0.7% mainly as a result of lower revenue at VITAS. See page 27 for additional VITAS operating metrics.

On April 1, 2013, Medicare reduced hospice reimbursement rates 2.0%. Effective October 1, 2013, Medicare increased the average hospice rate approximately 1.4% This effectively reduced Medicare hospice reimbursement 0.6% in the first quarter of 2014 when compared to the prior year quarter. VITAS expects its full-year 2014 revenue growth, prior to Medicare cap, to be in the range of 1.0% to 3.0%. Admissions in 2014 are estimated to increase 3.0% to 4.0%. Adjusted EBITDA margin, prior to Medicare cap, is estimated to be 14.5% to 15.0%. Medicare cap is estimated to be $5.0 million in 2014. Roto-Rooter expects full-year 2014 revenue growth of 3.0% to 4.0%. The revenue estimate is a result of increased job pricing of approximately 2.0%. Adjusted EBITDA margin for 2014 is estimated in the range of 19.0% to 20.0%. We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

\- 17 -

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2013 to March 31, 2014 include the following:

- A $24.4 million increase in accounts receivable related to the timing of Medicare receipts.
- A $6.5 million decrease in current deferred income taxes mainly related to the payment of litigation settlements.
- A $10.1 million decrease in accrued compensation related to the payment of incentive compensation in the first quarter.
- A $16.1 million decrease in accrued legal due to the payment of litigation settlements.

Net cash provided by operating activities decreased $20.0 million primarily as a result of the decrease in accounts payable and other current liabilities offset by the increase in accounts receivable. Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We have issued $35.0 million in standby letters of credit as of March 31, 2014, for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of March 31, 2014, we have approximately $315.0 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the $150 million expansion feature. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

### Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2014 and anticipate remaining in compliance throughout 2014.

The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including *qui tam* actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

On January 12, 2012, a putative class action lawsuit was filed in the U.S. District Court for the Southern District of Ohio against the Company, Kevin McNamara, David Williams, and Timothy O’Toole, *In re Chemed Corp. Securities Litigation*, Civil Action No. 1:12-cv-28 (S.D. Ohio). On June 18, 2012, an amended complaint was filed alleging violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 against all Defendants, and violation of Section 20(a) of the Securities Exchange Act of 1934 against Messrs. McNamara, Williams, and O’Toole. The suit’s allegations concern the VITAS hospice segment of the Company’s business. Plaintiffs seek, on behalf of a putative class of purchasers of Chemed Capital Stock, compensatory damages in an unspecified amount and attorneys’ fees and expenses, arising from Defendants’ alleged failure to disclose an alleged fraudulent scheme at VITAS to enroll ineligible hospice patients and to fraudulently obtain payments from the federal government. Defendants filed motions to dismiss the amended complaint on August 17, 2012, which were pending when the parties reached an agreement to settle the action. On June 7, 2013, following the filing of U.S. v. VITAS, discussed below, Plaintiffs filed a motion for leave to file a second amended complaint. Defendants opposed this motion. On September 16, 2013, Plaintiffs executed a Settlement Term Sheet with Defendants, reaching an agreement in principle to settle this case subject to Court approval. On February 6, 2014, Plaintiffs, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and May 2, 2013, inclusive, executed a stipulation of settlement with defendants, agreeing to settle this case in full and with prejudice, and to provide Defendants with full releases of all claims that are or could have been asserted by Plaintiffs in exchange for payment of $6.0 million by our insurer into a settlement fund for the benefit of the putative settlement class (“Settlement”). The Settlement of $6.0 million has been recorded as an accrual and offsetting prepaid in the accompanying Consolidated Balance Sheet. This Settlement received preliminary Court approval on March 27, 2014 and is scheduled for a final hearing on July 19, 2014. Defendants agreed to enter into this Settlement in order to eliminate the burden, expense and distraction of further litigation.

In June 2011, the U.S. Attorney provided the Company with a partially unsealed *qui tam* complaint filed under seal in the U.S. District Court for the Western District of Texas, *United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al.*, 5:08-cv-0663 (“*Urick”).* The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations. In June 2012, the complaint was unsealed. The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations. The suit was brought by Barbara Urick, a registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed. In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants. The complaint was served on the VITAS entities on April 12, 2013.

\- 18 -

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed *qui tam* complaint filed under seal in the U.S. District Court for the Northern District of Illinois, *United States, et al. ex rel. Spottiswood v. Chemed Corp.*, 1:07-cv-4566 (“*Spottiswood”).* In April 2012, the complaint was unsealed. The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations. Plaintiff filed an amended complaint in November 2012. The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services. The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate. The complaint was served on the defendants on April 12, 2013. On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in *Spottiswood* and in *Urick* on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries. The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, *United States v. VITAS Hospice Services, LLC, et al.*, No. 4:13-cv-00449-BCW (the “2013 Action”). Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed. The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course. This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest. On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action. The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS. The defendants filed a motion to dismiss on September 24, 2013.

On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a *qui tam* complaint against VITAS and VITAS Healthcare Corporation of California, *United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al.,* CV 12-0761-R (“*Gonzales”).* The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344. The government partially intervened in *Gonzales.* The *Gonzales* complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit. It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.

On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the *Spottiswood, Urick*, and *Gonzales* complaints with the 2013 Action. As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes. The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators. The Spottiswood relator filed an action under the Illinois False Claims Act, *The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation*, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014. The Court granted the parties’ joint motion to place this case on the its stay calendar, pending resolution of the 2013 Action.

VITAS has also received document subpoenas in related state matters. In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States. The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients. In September 2010, VITAS received a second CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees. In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.

\- 19 -

The net costs incurred related to U.S. v. Vitas and related regulatory matters were $748,000 and $1.0 million for the periods ending March 31, 2014 and 2013, respectively.

In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance. On November 6, 2013, KBC Asset Management NV filed suit in the United States Distrct Court for the District of Delaware, *KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al.*, No. 13 Civ. 1854 (LPS) (D. Del.). It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant. Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare. The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, *North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al.*, No. 13 Civ. 833 (MDB) (S.D. Ohio). She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant. Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls. The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants. The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole. Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On December 20, 2013, Plaintiff in the *North* action filed a motion before the Judicial Panel on Multidistrict Litigation seeking centralized treatment of her action and the *KBC* action in the U.S. District Court for the Southern District of Ohio. Defendants in both cases, as well as Plaintiff KBC, opposed that motion, consistent with Chemed’s By-law 8.07, which requires all derivative suits brought in Chemed’s name to proceed in federal or state court in Delaware. The MDL Panel denied the motion on April 2, 2014. On January 29, 2014 Defendants filed motions to transfer *North* to Delaware under 28 U.S.C § 1404 and to stay the case until after resolution of that motion and the MDL motion.

The Company intends to defend vigorously against the allegations in each of the above lawsuits. Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

\- 20 -

### Results of Operations

### Three months ended March 31, 2014 versus 2013 - Consolidated Results

Our service revenues and sales for the first quarter of 2014 decreased 2.3% versus services and sales revenues for the first quarter of 2013. Of this decrease, $10.9 million was attributable to VITAS offset by a $2.6 million increase at Roto-Rooter. The following chart shows the components of those changes (in thousands):

| VITAS | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| Routine homecare | $(1,263) | (0.6) |
| Continuous care | (7,150) | (15.8) |
| General inpatient | (2,475) | (8.7) |
| Medicare cap | (26) | (3.0) |
| Roto-Rooter |  |  |
| Plumbing | 3,796 | 8.8 |
| Drain cleaning | (1,367) | (3.6) |
| Contractor operations | 813 | 9.9 |
| Other | (669) | (11.1) |
| Total | $(8,341) | (2.3) |

The decrease in VITAS’ revenues for the first quarter of 2014 versus the first quarter of 2013 was a combination of Medicare reimbursement rates increasing approximately 1.4%, offset by a 2.0% decline due to sequestration, an ADC decrease of 0.8%, and geographical and level of care mix shift. In the first quarter of 2014, VITAS recorded a positive revenue adjustment of $847,000 related to eliminating the Medicare cap billing limitation recorded in the fourth quarter of 2013 for one program and partially eliminating the Medicare cap billing limitation in another program. This compares with $873,000 Medicare cap liability recorded in the first quarter of 2013. The ADC decrease was driven by a 0.2% increase in routine homecare, a decrease of 15.4% in continuous care and a decrease of 6.6% in general inpatient. In excess of 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the first quarter of 2014 versus 2013 is attributable to a 9.0% increase in job count offset by a 0.2% decrease in price and mix shift. Drain cleaning revenues for the first quarter of 2014 versus 2013 reflect a 7.9% decrease in the number of jobs performed offset by a 4.3% increase in price and mix shift. Contractor operations revenue increased 9.9% for the first quarter of 2014. Other Roto-Rooter revenue decreased 11.1%.

The consolidated gross margin was 28.0% in the first quarter of 2014 as compared with 27.9% in the first quarter of 2013. On a segment basis, VITAS’ gross margin was 21.1% in the first quarter of 2014 and 21.4% in the first quarter of 2013. The Roto-Rooter segment’s gross margin was 46.4% for the first quarter of 2014 as compared with 46.3% for the first quarter of 2013.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

| SG&A expenses before the impact of market gains of deferred compensation plans, | Three months ended March 31, 2014 | 2013 |
| --- | ---: | ---: |
| long-term incentive compensation, and OIG investigation expenses | **$53,388** | $52,437 |
| Long-term incentive compensation | **373** | 612 |
| Expenses related to OIG investigation | **748** | 1,039 |
| Impact of market value gains on liabilities held in deferred compensation |  |  |
| trusts | **1,162** | 1,472 |
| Total SG&A expenses | **$55,671** | $55,560 |

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans for the first quarter of 2014 were up 1.8% when compared to the first quarter of 2013 mainly as a result of normal salary increases.

\- 21 -

Other income - net comprise (in thousands):

| Market value gains on assets held in deferred | Three months ended March 31, 2014 | 2013 |
| --- | ---: | ---: |
| compensation trusts | **$1,162** | $1,472 |
| Loss on disposal of property and equipment | **(278)** | (78) |
| Interest income - net | **(50)** | 303 |
| Other | **(18)** | 9 |
| Total other income - net | **$816** | $1,706 |

Our effective income tax rate was 38.9% in the first quarter of 2014 which is flat when compared to the first quarter of 2013.

Net income for both periods included the following after-tax items/adjustments that reduced or increased after-tax earnings (in thousands):

| VITAS | Three months ended March 31, 2014 | 2013 |
| --- | ---: | ---: |
| Expenses related to OIG investigation | **$(464)** | $(644) |
| Expenses related to litigation settlements | **(70)** | - |
| Acquisition expenses | **(1)** | - |
| Roto-Rooter |  |  |
| Expenses related to litigation settlements | **(117)** | (86) |
| Expenses of severance arrangements | **-** | (184) |
| Corporate |  |  |
| Noncash impact of change in accounting for convertible debt | **(1,429)** | (1,323) |
| Stock option expense | **(822)** | (943) |
| Long-term incentive compensation | **(236)** | (387) |
| Loss on extinguishment of debt | **-** | (294) |
| Expenses related to securities litigation | **-** | (1) |
| Total | **$(3,139)** | $(3,862) |

### Three months ended March 31, 2014 versus 2013 - Segment Results

The change in after-tax earnings for the first quarter of 2014 versus the first quarter of 2013 is due to (in thousands):

|  | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| VITAS | $(1,983) | (9.8) |
| Roto-Rooter | 409 | 4.2 |
| Corporate | (130) | (1.7) |
|  | $(1,704) | (7.6) |

\- 22 -

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2014*

*(in thousands)(unaudited)*

| 2014 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $260,412 | $97,888 | $- | $358,300 |
| Cost of services provided and goods sold | 205,392 | 52,427 | - | 257,819 |
| Selling, general and administrative expenses | 21,714 | 27,181 | 6,776 | 55,671 |
| Depreciation | 4,614 | 2,399 | 136 | 7,149 |
| Amortization | 419 | 145 | 445 | 1,009 |
| Total costs and expenses | 232,139 | 82,152 | 7,357 | 321,648 |
| Income/(loss) from operations | 28,273 | 15,736 | (7,357) | 36,652 |
| Interest expense | (56) | (97) | (3,662) | (3,815) |
| Intercompany interest income/(expense) | 1,344 | 649 | (1,993) | - |
| Other income/(expense)—net | (293) | (59) | 1,168 | 816 |
| Income/(expense) before income taxes | 29,268 | 16,229 | (11,844) | 33,653 |
| Income taxes | (11,109) | (6,196) | 4,226 | (13,079) |
| Net income/(loss) | $18,159 | $10,033 | $(7,618) | $20,574 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(1,309) | $(1,309) |
| Noncash impact of accounting for convertible debt | - | - | (2,259) | (2,259) |
| Long-term incentive compensation | - | - | (373) | (373) |
| Expenses related to litigation settlements | (113) | (193) | - | (306) |
| Acquisition expenses | (1) | - | - | (1) |
| Expenses related to OIG investigation | (748) | - | - | (748) |
| Total | $(862) | $(193) | $(3,941) | $(4,996) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(822) | $(822) |
| Noncash impact of accounting for convertible debt | - | - | (1,429) | (1,429) |
| Long-term incentive compensation | - | - | (236) | (236) |
| Expenses related to litigation settlements | (70) | (117) | - | (187) |
| Acquisition expenses | (1) | - | - | (1) |
| Expenses related to OIG investigation | (464) | - | - | (464) |
| Total | $(535) | $(117) | $(2,487) | $(3,139) |

\- 23 -

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2013*

*(in thousands)(unaudited)*

| 2013 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $271,326 | $95,315 | $- | $366,641 |
| Cost of services provided and goods sold | 213,160 | 51,147 | - | 264,307 |
| Selling, general and administrative expenses | 21,604 | 26,662 | 7,294 | 55,560 |
| Depreciation | 4,514 | 2,147 | 134 | 6,795 |
| Amortization | 491 | 154 | 482 | 1,127 |
| Total costs and expenses | 239,769 | 80,110 | 7,910 | 327,789 |
| Income/(loss) from operations | 31,557 | 15,205 | (7,910) | 38,852 |
| Interest expense | (46) | (59) | (3,989) | (4,094) |
| Intercompany interest income/(expense) | 843 | 428 | (1,271) | - |
| Other income/(expense)—net | 221 | (1) | 1,486 | 1,706 |
| Income/(expense) before income taxes | 32,575 | 15,573 | (11,684) | 36,464 |
| Income taxes | (12,433) | (5,949) | 4,196 | (14,186) |
| Net income/(loss) | $20,142 | $9,624 | $(7,488) | $22,278 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(1,491) | $(1,491) |
| Noncash impact of accounting for convertible debt | - | - | (2,091) | (2,091) |
| Long-term incentive compensation | - | - | (612) | (612) |
| Expenses of severance arrangements | - | (302) | - | (302) |
| Loss on extinguishment of debt | - | - | (465) | (465) |
| Expenses related to litigation settlement | - | (141) | - | (141) |
| Expenses related to securities litigation | - | - | (2) | (2) |
| Acquisition expenses | (1) | - | - | (1) |
| Expenses of OIG investigation | (1,039) | - | - | (1,039) |
| Total | $(1,040) | $(443) | $(4,661) | $(6,144) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(943) | $(943) |
| Noncash impact of accounting for convertible debt | - | - | (1,323) | (1,323) |
| Long-term incentive compensation | - | - | (387) | (387) |
| Expenses of severance arrangements | - | (184) | - | (184) |
| Loss on extinguishment of debt | - | - | (294) | (294) |
| Expenses related to litigation settlements | - | (86) | - | (86) |
| Expenses related to securities litigation | - | - | (1) | (1) |
| Expenses of OIG investigation | (644) | - | - | (644) |
| Total | $(644) | $(270) | $(2,948) | $(3,862) |

\- 24 -

*Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2014 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $18,159 | $10,033 | $(7,618) | $20,574 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 56 | 97 | 3,662 | 3,815 |
| Income taxes | 11,109 | 6,196 | (4,226) | 13,079 |
| Depreciation | 4,614 | 2,399 | 136 | 7,149 |
| Amortization | 419 | 145 | 445 | 1,009 |
| **EBITDA** | 34,357 | 18,870 | (7,601) | 45,626 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (1,344) | (649) | 1,993 | - |
| Interest income | 64 | (8) | (6) | 50 |
| Expenses related to OIG investigation | 748 | - | - | 748 |
| Acquisition expenses | 1 | - | - | 1 |
| Expenses related to litigation settlements | 113 | 193 | - | 306 |
| Advertising cost adjustment | - | (741) | - | (741) |
| Stock option expense | - | - | 1,309 | 1,309 |
| Long-term incentive compensation | - | - | 373 | 373 |
| **Adjusted EBITDA** | $33,939 | $17,665 | $(3,932) | $47,672 |
|  |  |  |  | **Chemed** |
| For the three months ended March 31, 2013 | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **Net income/(loss)** | $20,142 | $9,624 | $(7,488) | $22,278 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 46 | 59 | 3,989 | 4,094 |
| Income taxes | 12,433 | 5,949 | (4,196) | 14,186 |
| Depreciation | 4,514 | 2,147 | 134 | 6,795 |
| Amortization | 491 | 154 | 482 | 1,127 |
| **EBITDA** | 37,626 | 17,933 | (7,079) | 48,480 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (843) | (428) | 1,271 | - |
| Interest income | (246) | (42) | (15) | (303) |
| Expenses related to OIG investigation | 1,039 | - | - | 1,039 |
| Acquisition expenses | 1 | - | - | 1 |
| Expenses of severance arrangements | - | 302 | - | 302 |
| Advertising cost adjustment | - | (469) | - | (469) |
| Expenses related to litigation settlements | - | 141 | - | 141 |
| Long-term incentive compensation | - | - | 612 | 612 |
| Stock option expense | - | - | 1,491 | 1,491 |
| Expenses related to securities litigation | - | - | 2 | 2 |
| **Adjusted EBITDA** | $37,577 | $17,437 | $(3,718) | $51,296 |

\- 25 -

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*RECONCILIATION OF ADJUSTED NET INCOME*

*(in thousands, except per share data)(unaudited)*

|  | Three Months Ended March 31, 2014 | 2013 |
| --- | ---: | ---: |
| Net income as reported | **$20,574** | $22,278 |
| Add/(deduct) after-tax cost of: |  |  |
| Additional interest expense resulting from the change in accounting |  |  |
| for the conversion feature of the convertible notes | **1,429** | 1,323 |
| Stock option expense | **822** | 943 |
| Expenses of OIG investigation | **464** | 644 |
| Long-term incentive compensation | **236** | 387 |
| Expenses related to litigation settlements | **187** | 86 |
| Acquisition expenses | **1** | - |
| Loss on extinguishment of debt | **-** | 294 |
| Expenses of severance arrangements | **-** | 184 |
| Expenses related to securities litigation | **-** | 1 |
| Adjusted net income | **$23,713** | $26,140 |
| Diluted Earnings Per Share As Reported |  |  |
| Net income | **$1.12** | $1.17 |
| Average number of shares outstanding | **18,305** | 19,000 |
| Adjusted Diluted Earnings Per Share |  |  |
| Adjusted net income | **$1.32** | $1.38 |
| Adjusted average number of shares outstanding\* | **18,019** | 19,000 |
| \* Adjusted diluted average shares outstanding exludes the estimated dilutive impact of the Convertible Notes (285,000 share for the first quarter of 2014) as this impact will be offset entirely by the Convertible Note Hedges when such conversion occurs in the second quarter of 2014. |  |  |

\- 26 -

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*OPERATING STATISTICS FOR VITAS SEGMENT*

*(unaudited)*

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended March 31, 2014 | 2013 |
| --- | ---: | ---: |
| Homecare | **$195,397** | $196,660 |
| Inpatient | **25,993** | 28,468 |
| Continuous care | **38,175** | 45,325 |
| Total before Medicare cap allowance | **$259,565** | $270,453 |
| Medicare cap allowance | **847** | 873 |
| Total | **$260,412** | $271,326 |
| Net revenue as a percent of total |  |  |
| before Medicare cap allowance |  |  |
| Homecare | **75.3%** | 72.7% |
| Inpatient | **10.0** | 10.5 |
| Continuous care | **14.7** | 16.8 |
| Total before Medicare cap allowance | **100.0** | 100.0 |
| Medicare cap allowance | **0.3** | 0.3 |
| Total | **100.3%** | 100.3% |
| Average daily census (days) |  |  |
| Homecare | **10,476** | 10,354 |
| Nursing home | **2,828** | 2,929 |
| Routine homecare | **13,304** | 13,283 |
| Inpatient | **437** | 468 |
| Continuous care | **576** | 681 |
| Total | **14,317** | 14,432 |
| Total Admissions | **16,353** | 17,137 |
| Total Discharges | **16,002** | 16,843 |
| Average length of stay (days) | **81.1** | 77.4 |
| Median length of stay (days) | **14.0** | 13.0 |
| ADC by major diagnosis |  |  |
| Neurological | **39.2%** | 33.2% |
| Cancer | **17.3** | 16.9 |
| Cardio | **14.7** | 11.2 |
| Respiratory | **3.3** | 6.9 |
| Other | **25.5** | 31.8 |
| Total | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |
| Neurological | **21.8** | 19.2% |
| Cancer | **32.4** | 30.8 |
| Cardio | **13.8** | 11.6 |
| Respiratory | **9.9** | 9.6 |
| Other | **22.1** | 28.8 |
| Total | **100.0%** | 100.0% |
| Direct patient care margins |  |  |
| Routine homecare | **52.8%** | 51.9% |
| Inpatient | **4.2** | 10.9 |
| Continuous care | **16.6** | 17.7 |
| Homecare margin drivers (dollars per patient day) |  |  |
| Labor costs | **$55.44** | $57.18 |
| Drug costs | **7.24** | 7.57 |
| Home medical equipment | **6.61** | 6.85 |
| Medical supplies | **3.22** | 2.92 |
| Inpatient margin drivers (dollars per patient day) |  |  |
| Labor costs | **$349.71** | $320.67 |
| Continuous care margin drivers (dollars per patient day) |  |  |
| Labor costs | **$593.77** | $587.73 |
| Bad debt expense as a percent of revenues | **1.0%** | 0.8% |
| Accounts receivable -- |  |  |
| Days of revenue outstanding- excluding unapplied Medicare payments | **42.7** | 39.0 |
| Days of revenue outstanding- including unapplied Medicare payments | **33.8** | 29.6 |

\- 27 -

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

## Market risk

As filed, 293 characters.

Our primary market risk exposure relates to interest rate risk exposure through variable interest rate borrowings. At March 31, 2014, we had no variable rate debt outstanding. At March 31, 2014, the fair value of the Notes approximates $209.2 million which have a face value of $187.0 million.

## Controls and procedures

As filed, 900 characters.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 144 characters.

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

\- 28 -

Filed May 2, 2014.
Source: SEC EDGAR, the filing index for accession 0001157523-14-001833. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
